Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB™ platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR® AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.
This expansion marks a significant step in applying artificial intelligence to drug development, allowing researchers to obtain detailed molecular profiles quickly without the need for extensive computational resources. The platform is now accessible via the web, making it easier for scientists worldwide to utilize these advanced analytics. By integrating with Lantern’s existing AI capabilities, the predictBBB LQM aims to reduce the time and cost associated with early-stage drug discovery, potentially accelerating the development of new therapies.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR® platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
In addition to its pipeline, Lantern’s withZeta.ai platform is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The expansion of predictBBB into an LQM underscores Lantern’s commitment to broadening access to advanced computational tools for drug discovery. By providing benchmark-validated performance and real-time analysis, the platform aims to empower researchers to make more informed decisions earlier in the development process. This move may also strengthen Lantern’s position in the AI-driven drug discovery space, potentially attracting partnerships and collaborations.
For more details, the full press release is available at this link. Additional information about Lantern Pharma and its technologies can be found on their website.
